Search

Displaying results 3321 - 3330 of 10000 in total
  1. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

  2. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity … The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion

  3. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.

  4. Drug

    Mebutamate

    go.drugbank.com/drugs/DB06797
    Approved

    Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a

  5. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma

    Synonyms: N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
  6. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    AZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.

  7. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.

  8. Drug

    Faznolutamide

    go.drugbank.com/drugs/DB21612
    Experimental

    The usage of the INN stem '-lutamide' in the name indicates that Faznolutamide is a non-steroid antiandrogen. Faznolutamide has a monoisotopic molecular weight of 384.11 Da.

  9. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). CoFactor use with 5-FU is being evaluated in cli...

  10. Target

    Death-associated protein kinase 3

    go.drugbank.com/bio_entities/BE0003788
    TargetHumans

    Regulates myosin phosphorylation in both smooth muscle and non-muscle cells. … Phosphorylates MYL12B in non-muscle cells leading to reorganization of actin cytoskeleton. Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B.

    Synonyms: DAP kinase 3, DAP-like kinase